Clinical trial
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
NCT03782376 is registered in ClinicalTrials.gov with Janssen-Cilag Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
- Lead sponsor
- Janssen-Cilag Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 20, 2018
- Completion date
- January 10, 2023
- Enrollment
- 215 (actual)
- Sites
- 104
Conditions
As the registry lists them; a condition with its own page is linked.